Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489176 · ClinicalTrials.gov registry record · Phase 3
Regadenoson Real Time Perfusion Imaging Trial-Optison
A Phase 3 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT01489176: Completed Phase 3 study, sponsored by University of Nebraska.
NCT01489176 is a Phase 3 study that has completed, run by University of Nebraska. The registered enrollment target is 50 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01489176, a Phase 3 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose if this study is to examine how effective Regadenoson is in detecting coronary artery disease during a stress echocardiogram when Optison is administered. Optison is a contrast agent that improves the images of the heart on the echocardiogram (echo) machine. Optison is approved by the Food and Drug Administration (FDA) to use during stress echocardiograms. Regadenoson is a commercially available rapid acting stress agent that is used to chemically increase the heart rate and is approved for nuclear imaging tests. Regadenoson is a FDA approved drug but not for the intended use in this study.
Primary Outcome
Measurements will be analyzed to identify a coronary stenosis \>50% in diameter by quantitative cardiac angiography.
Interventions
- DRUG Regadenoson; Optison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-07-31 |
| Est. Completion | 2014-12-01 |
| Phase | Phase 3 |
What the finished NCT01489176 record still lists
NCT01489176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Regadenoson; Optison is the first listed.
NCT01489176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01489176 about?
NCT01489176 is a clinical study titled "Regadenoson Real Time Perfusion Imaging Trial-Optison". The purpose if this study is to examine how effective Regadenoson is in detecting coronary artery disease during a stress echocardiogram when Optison is administered. Optison is a contrast agent that improves the images of the heart on the echocardiogram (echo) machine. Optison is approved by the Fo...
What is the current status of trial NCT01489176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2012-07-31. Estimated completion is 2014-12-01.
What interventions are being tested in trial NCT01489176?
The interventions under investigation include: Regadenoson; Optison (DRUG).
Who is sponsoring clinical trial NCT01489176?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01489176's enrollment target sits among peer trials
50 1844th of 2000 higher than 141 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI